Boston Scientific Corporation, a global medical technology leader, has reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System to the Cobalt Chromium (CoCr) Xience V Everolimus-Eluting Coronary Stent System.
At three years, the PROMUS Element Stent continued to demonstrate advantages over the Xience V Stent. This data were presented by Ian Meredith, MD, Monash University, Melbourne, Australia, at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco.
Stents, which are placed and expanded to fit the size, shape and bend of the artery, may also be coated with a drug. Boston Scientific is continuously studying product performance in an effort to offer innovations that provide a positive impact on patient care and lower the costs of healthcare.
"The PROMUS Element Platinum Chromium Stent continues to demonstrate excellent safety and effectiveness with low rates of cardiac death, myocardial infarction, stent thrombosis and repeat revascularization," said Prof. Meredith. "These three-year results confirm that this device benefits patients with symptomatic coronary artery disease requiring Percutaneous Coronary Intervention."
The trial reported a three-year target lesion revascularization (TLR) rate of 3.5 per cent for the PROMUS Element Stent, the lowest TLR rate in any pivotal FDA approval trial, compared to 4.9 per cent for the Xience V Stent (p=0.21). Both the PROMUS Element and Xience V Stents demonstrated low rates of ARC/Definite stent thrombosis of 0.7 per cent and 0.5 per cent respectively (p=0.76). Trial results also confirmed a previously reported significant reduction in unplanned (bail-out or emergency) stenting with the PROMUS Element Stent compared to the Xience V Stent (5.9 per cent vs. 9.8 per cent, p=0.004), including a significantly lower rate of inadequate lesion coverage (1.4 per cent vs. 3.4 per cent, p=0.01). These clinical observations reinforce the results of comparative bench and pre-clinical studies, which have demonstrated the enhanced visibility and deliverability of the PROMUS Element Stent relative to the Xience V Stent. The reduction in bail-out stenting has also been tied to cost savings per procedure.
"With its outstanding deliverability, conformability and visibility, the PROMUS Element Stent offers interventional cardiologists an exceptional stenting option for patients with coronary artery disease," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "These data confirm consistent long term performance which supports our efforts to improve the lives of patients around the world."
Separately, Jeffrey Popma, MD, Beth Israel Deaconess Medical Centre, Boston, presented data that demonstrated significantly less vessel straightening, which may be associated with improved blood flow within the vessel, when using the conformable PROMUS Element Stent compared to the more rigid Xience V stent (40 per cent relative reduction in angulation change from pre to post procedure with PROMUS Element, P=0.01).
"The PLATINUM three-year results support the theory that platform matters," said Popma. "The flexible and conformable platinum chromium PROMUS Element Stent causes less vessel straightening than Xience stents, possibly contributing to the low clinical event rates observed at three years with PROMUS Element Stents."
The PROMUS Element Stent, utilized in the PROMUS Element Stent System and the PROMUS Element Plus Stent System, uses a proprietary platinum chromium alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, high fracture resistance, excellent conformability and higher radial strength. The PROMUS Element Plus Stent System features an advanced low-profile delivery system to facilitate precise delivery of the stent across challenging lesions.
Xience V is a trademark of the Abbott Laboratories group of companies.